MX370481B - Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. - Google Patents
Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.Info
- Publication number
- MX370481B MX370481B MX2017012736A MX2017012736A MX370481B MX 370481 B MX370481 B MX 370481B MX 2017012736 A MX2017012736 A MX 2017012736A MX 2017012736 A MX2017012736 A MX 2017012736A MX 370481 B MX370481 B MX 370481B
- Authority
- MX
- Mexico
- Prior art keywords
- vectors containing
- clones
- signal sequence
- polya signal
- productivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
En la presente se reporta que para transfecciones transitorias el uso del promotor alfa de factor 1 de elongación humano (con el intrón A) proporciona una productividad mejorada (en organización de LC-HC-SM), el uso de la secuencia de señal poliA de hormona del crecimiento bovina proporciona una productividad mejorada en comparación con el uso de la secuencia de señal poliA de SV40, la adición de hGT a la secuencia de señal poliA de bGH resulta en una productividad aumentada en vectores que contienen el promotor hCMV y la organización de vector CL (3'-5')-HC-SM resulta en expresión mejorada. Para acumulados estables se reporta que acumulados generados con vectores que contienen el promotor a de hEF1 muestran una productividad mejorada en análisis por lotes, clones generados con los vectores que contienen el promotor hEF1a muestran un número reducido de clones poco productores, y los clones generados con vectores que contienen el promotor hEF1a muestran una mayor estabilidad de expresión de IgG. Para clones únicos se reporta que la organización del vector con la posición corriente abajo del marcador de selección (LC-HC-SM) tiene un efecto positivo sobre la productividad de clones únicos y que los clones generados con vectores que contienen la secuencia de señal poliA de bGH y hGT tienen las mayores productividades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11195361 | 2011-12-22 | ||
PCT/EP2012/076203 WO2013092743A2 (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX370481B true MX370481B (es) | 2019-12-16 |
Family
ID=47504950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007359A MX355624B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. |
MX2017012736A MX370481B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007359A MX355624B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20160208284A1 (es) |
EP (2) | EP3354660A1 (es) |
JP (4) | JP6096802B2 (es) |
KR (4) | KR102285184B1 (es) |
CN (4) | CN113896787A (es) |
BR (1) | BR112014014239B1 (es) |
CA (2) | CA3149402A1 (es) |
ES (1) | ES2930215T3 (es) |
HK (1) | HK1200848A1 (es) |
HR (1) | HRP20221383T1 (es) |
MX (2) | MX355624B (es) |
PL (1) | PL2794651T3 (es) |
RU (2) | RU2756910C2 (es) |
SG (3) | SG10201900915WA (es) |
WO (1) | WO2013092743A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3149402A1 (en) * | 2011-12-22 | 2013-06-27 | F. Hoffman-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
EP3683314A1 (en) * | 2013-10-07 | 2020-07-22 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
CN105255867A (zh) * | 2015-10-19 | 2016-01-20 | 北京益生合生物科技有限公司 | 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用 |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
CN110022904B (zh) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
JP7282689B2 (ja) * | 2017-05-19 | 2023-05-29 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | リフォールディングした組み換えヒト化ラニビズマブの製造方法 |
JP7081139B2 (ja) * | 2017-12-20 | 2022-06-07 | 東ソー株式会社 | 新規プロモーターおよびそれを含む発現ベクター |
BR112021005115A2 (pt) * | 2018-09-20 | 2021-06-15 | Sanofi | métodos e composições de clonagem universal baseada em íntron |
KR102559149B1 (ko) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
TW202237657A (zh) | 2021-01-29 | 2022-10-01 | 美商默沙東藥廠 | 計畫性死亡受體1(pd-1)抗體之組合物及獲得該組合物之方法 |
KR102640929B1 (ko) | 2023-06-02 | 2024-02-27 | (주) 멥스젠 | 미세생체조직시스템 형성 장치 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
RU2201449C2 (ru) * | 1994-10-14 | 2003-03-27 | Сембайозис Дженетикс Инк. | Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
EP1308517A1 (en) * | 2001-10-31 | 2003-05-07 | Aventis Pharmacueticals Products Inc. | Vectors for expressing multiple transgenes |
CN1585822A (zh) * | 2001-11-16 | 2005-02-23 | 拜奥根Idec公司 | 抗体的多顺反子表达 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
CN100383244C (zh) * | 2003-01-07 | 2008-04-23 | 西福根有限公司 | 用于生产重组多克隆蛋白质的方法 |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
SI2116605T1 (sl) * | 2004-06-17 | 2012-07-31 | Wyeth Llc | Plazmid s tremi popolnimi transkripcijskimi enotami in imunogeni sestavki za induciranje imunskega odgovora na HIV |
TW200732472A (en) * | 2005-10-21 | 2007-09-01 | Hoffmann La Roche | Method for the recombinant expression of a polypeptide |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
CN101563460A (zh) * | 2006-12-22 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | 选择方法 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
BRPI0809361A2 (pt) * | 2007-03-30 | 2014-09-02 | Abbott Lab | Elementos de vetor de expressão recombinante (reves) para melhorar a expressão de proteínas recombinantes em células hospedeiras |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CN101688222B (zh) * | 2007-06-29 | 2013-03-06 | 弗·哈夫曼-拉罗切有限公司 | 启动子 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
PL2329020T3 (pl) * | 2008-08-28 | 2013-08-30 | Novartis Ag | Prezentacja izoform polipeptydu na powierzchni komórki poprzez nadczytywanie kodonu stop |
GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
MX2011010159A (es) | 2009-04-02 | 2011-10-17 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
CA3149402A1 (en) * | 2011-12-22 | 2013-06-27 | F. Hoffman-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
-
2012
- 2012-12-19 CA CA3149402A patent/CA3149402A1/en active Pending
- 2012-12-19 CA CA2854249A patent/CA2854249C/en active Active
- 2012-12-19 RU RU2017140661A patent/RU2756910C2/ru active
- 2012-12-19 HR HRP20221383TT patent/HRP20221383T1/hr unknown
- 2012-12-19 PL PL12810245.6T patent/PL2794651T3/pl unknown
- 2012-12-19 CN CN202111171021.6A patent/CN113896787A/zh active Pending
- 2012-12-19 MX MX2014007359A patent/MX355624B/es active IP Right Grant
- 2012-12-19 EP EP18157484.9A patent/EP3354660A1/en active Pending
- 2012-12-19 KR KR1020217007341A patent/KR102285184B1/ko active IP Right Grant
- 2012-12-19 US US14/367,680 patent/US20160208284A1/en not_active Abandoned
- 2012-12-19 SG SG10201900915WA patent/SG10201900915WA/en unknown
- 2012-12-19 SG SG11201403443WA patent/SG11201403443WA/en unknown
- 2012-12-19 CN CN201710324350.7A patent/CN107119073A/zh active Pending
- 2012-12-19 CN CN201280062793.9A patent/CN104011075B/zh active Active
- 2012-12-19 MX MX2017012736A patent/MX370481B/es unknown
- 2012-12-19 KR KR1020207007391A patent/KR102229491B1/ko active IP Right Grant
- 2012-12-19 KR KR1020197034166A patent/KR102166824B1/ko active IP Right Grant
- 2012-12-19 KR KR1020147016825A patent/KR102048556B1/ko active IP Right Grant
- 2012-12-19 CN CN202111170578.8A patent/CN113881702A/zh active Pending
- 2012-12-19 SG SG10201700169PA patent/SG10201700169PA/en unknown
- 2012-12-19 BR BR112014014239-4A patent/BR112014014239B1/pt active IP Right Grant
- 2012-12-19 JP JP2014547983A patent/JP6096802B2/ja active Active
- 2012-12-19 RU RU2014129727A patent/RU2639519C2/ru active
- 2012-12-19 ES ES12810245T patent/ES2930215T3/es active Active
- 2012-12-19 WO PCT/EP2012/076203 patent/WO2013092743A2/en active Application Filing
- 2012-12-19 EP EP12810245.6A patent/EP2794651B1/en active Active
-
2015
- 2015-02-04 HK HK15101213.2A patent/HK1200848A1/xx unknown
-
2017
- 2017-02-16 JP JP2017026502A patent/JP6417436B2/ja active Active
-
2018
- 2018-10-05 JP JP2018189605A patent/JP2019030311A/ja active Pending
-
2019
- 2019-12-09 JP JP2019221805A patent/JP7096806B2/ja active Active
-
2020
- 2020-07-06 US US16/921,194 patent/US20210024952A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX370481B (es) | Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. | |
FI3536797T3 (fi) | Siirtogeenin tehostettu ilmentäminen ja prosessointi | |
HRP20170380T1 (hr) | Životinje s humaniziranim il-5 | |
WO2015042557A4 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
AR078544A1 (es) | Procedimiento de cultivo de celulas de mamiferos para la produccion de proteinas | |
BR112014014913A2 (pt) | mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa | |
MY157086A (en) | Cells for producing recombinant iduronate-2-sulfatase | |
RU2015112607A (ru) | Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования | |
MX2015012361A (es) | Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. | |
NZ733113A (en) | Methods of producing long acting ctp-modified growth hormone polypeptides | |
SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
HRP20200744T1 (hr) | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida | |
WO2007003582A3 (en) | Serum-free stable transfection and production of recombinant human proteins in human cell lines | |
MX371007B (es) | Vectores de expresión que comprenden un promotor de citomegalovirus quimérico y secuencias mejoradoras. | |
MY161552A (en) | A polynucleotide and polypeptide sequence and methods thereof | |
NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
JP2015516156A5 (es) | ||
MX2019003256A (es) | Vectores basados en el virus de la tristeza de los citricos para la expresion de gen/es ajenos. | |
CN104974226B (zh) | 一种用于蛋白质表达的信号肽 | |
WO2013032999A3 (en) | Polydnavirus vectors | |
MX352229B (es) | Metodo de produccion de polipeptido recombinante. | |
MX2013013937A (es) | Anticuerpos del receptor eritropoyetina (epo) anti-humana y metodos de uso. | |
MX2015013842A (es) | Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero. | |
WO2020068014A3 (en) | Tetrahymena thermophila artificial chromosome 1 (ttac1) and its use for the production of recombinant proteins | |
RU2013123459A (ru) | Плазмида для экспрессии рекомбинантного фактора свертываемости крови viii человека с делетированным в-доменом, моноклональная линия клеток млекопитающего - продуцент рекомбинантного фактора свертываемости крови viii человека с делетированным в-доменом и способ получения указанного фактора |